摘要
这家生物技术公司利用人工智能让医生分享挽救生命的研究,在“奥金”这家人工智能生物科技公司,共同创始人兼首席执行官托马斯·克洛泽尔正在通过一种全新的观点,重新思考癌症与疾病研究,同时试图打破医疗保健界的重重障碍。“医学界的研究领域相当孤立,”克洛泽尔说,“医疗其实不存在公开的创新。”身为临床研究医生以及临床血液学前助理教授,克洛泽尔亲眼目睹了那种孤立现象。他看到病患需要更有效的药物,需要依据他们的病情与生物构造量身定做,从而意识到搜集不同机构的研究是推进药物研发的最佳方法。
At AI biotech company Owkin,cofounder and CEO Thomas Clozel is rethinking cancer and disease research through an entirely new lens-and aiming to break down barriers in healthcare along the way."The field of research in medicine is extremely siloed,"Clozel says."Open innovation in health doesn't really exist."As a clinical research doctor and former assistant professor in clinical hematology,Clozel witnessed these silos firsthand.He saw that patients needed more effective drugs,tailored to their specific conditions and biology-and realized that gathering research across institutions was the best path toward better drug development.
